Cytokinetics Inc’s recent filing unveils that its Officer ANDREW CALLOS acquired Company’s shares for reported $0.11 million on Dec 29 ’25. In the deal valued at $63.11 per share,1,809 shares were bought.
Then, WIERENGA WENDELL sold 20,000 shares, generating $1,322,800 in total proceeds. Upon selling the shares at $66.14, the Director now owns 32,444 shares.
Before that, WENDELL WIERENGA bought 20,000 shares. Cytokinetics Inc shares valued at $1,254,400 were divested by the Director at a price of $62.72 per share.
Goldman upgraded its Cytokinetics Inc [CYTK] rating to a Buy from a a Neutral in a research note published recently. Barclays began covering CYTK with “an Overweight” recommendation on April 24, 2025. Citigroup started covering the stock on February 07, 2025. It rated CYTK as “a Buy”.
Price Performance Review of CYTK
On Monday, Cytokinetics Inc [NASDAQ:CYTK] saw its stock fall -2.15% to $61.75. Over the last five days, the stock has lost -1.55%. Cytokinetics Inc shares have risen nearly 27.24% since the year began. Nevertheless, the stocks have risen 31.27% over the past one year. While a 52-week high of $70.98 was reached on 12/22/25, a 52-week low of $29.31 was recorded on 05/15/25.
Levels Of Support And Resistance For CYTK Stock
The 24-hour chart illustrates a support level at 61.32, which if violated will result in even more drops to 60.89. On the upside, there is a resistance level at 62.45. A further resistance level may holdings at 63.15.
How much short interest is there in Cytokinetics Inc?
A steep rise in short interest was recorded in Cytokinetics Inc stocks on 2025-12-15, dropping by -1.04 million shares to a total of 13.34 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-14 was 14.38 million shares. There was a decline of -7.8%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on January 22, 2025 when Stifel began covering the stock and recommended ‘”a Buy”‘ rating along with a $80 price target.
